Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy (pages 1114–1123).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
TLR2/4 deficiency prevents oxygen-induced vascular degeneration and promotes revascularization by downregulating IL-17 in the retina
Scientific Reports Open Access 14 June 2016
-
Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors
Cell & Bioscience Open Access 23 December 2015
-
Compensatory angiogenesis and tumor refractoriness
Oncogenesis Open Access 01 June 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Marina Corral Spence
References
Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).
Ferrara, N. & Kerbel, R.S. Nature 438, 967–974 (2005).
Kieran, M.W., Kalluri, R. & Cho, Y.J. Cold Spring Harb. Perspect. Med. 2, a006593 (2012).
Leek, R.D., Harris, A.L. & Lewis, C.E. J. Leukoc. Biol. 56, 423–435 (1994).
Holash, J. et al. Science 284, 1994–1998 (1999).
Chung, A.S. et al. Nat. Med. 19, 1114–1123 (2013).
McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217–228 (2013).
De Palma, M. & Lewis, C. Cancer Cell 23 Issue 3, 277–286 (2013).
Du, R. et al. Cancer Cell 13, 206–220 (2008).
Bergers, G. & Song, S. Neuro Oncol. 7, 452–464 (2005).
De Palma, M. et al. Cancer Cell 8, 211–226 (2005).
Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. Nat. Rev. Immunol. 12, 253–268 (2012).
Crawford, Y. et al. Cancer Cell 15, 21–34 (2009).
Shojaei, F. et al. Nat. Biotechnol. 25, 911–920 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Maniati, E., Hagemann, T. IL-17 mediates resistance to anti-VEGF therapy. Nat Med 19, 1092–1094 (2013). https://doi.org/10.1038/nm.3333
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3333
This article is cited by
-
Current status and future of anti-angiogenic drugs in lung cancer
Clinical and Experimental Medicine (2023)
-
TLR2/4 deficiency prevents oxygen-induced vascular degeneration and promotes revascularization by downregulating IL-17 in the retina
Scientific Reports (2016)
-
Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors
Cell & Bioscience (2015)
-
Compensatory angiogenesis and tumor refractoriness
Oncogenesis (2015)
